anti-trbv9 monoclonal antibody

mAbexperimental

Clinical trial activity

2 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0

Earliest trial started Apr 19, 2022 (NCT05445076)

Timeline

2020s

  1. Jan 1, 2022

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2023

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06333210Phase 3Dec 25, 2023Biocad
NCT05445076Phase 2Apr 19, 2022Biocad
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
BiocadFor profit2222022
1 organizations
Page 1 / 1